Pediatric Oncology Daily Report: 01/23/2024

A phase 3, FORUM study evaluated two total body irradiation (TBI)-free chemotherapeutic conditioning regimens in 191 children aged <4 years with ALL undergoing allogeneic hematopoietic stem cell transplantation (HSCT) (1). The study found a 3-year overall survival (OS) of 0.63 (95% CI, 0.52-0.72) for the fludarabine/thiotepa/busulfan regimen and 0.76 (95% CI, 0.64-0.84) for the fludarabine/thiotepa/treosulfan regimen. The 3-year event-free survival (EFS) was 0.52 and 0.51, respectively. The cumulative incidence of nonrelapse mortality at 3 years was 0.06 vs 0.03. This trial is registered at clinicaltrials.gov as #NCT01949129.

Reference

Bader P, Pötschger U, Dalle JH, Moser LM, Balduzzi A, Ansari M, Buechner J, Güngör T, Ifversen M, Krivan G, Pichler H, Renard M, Staciuk R, Sedlacek P, Stein J, Heusel JR, Truong T, Wachowiak J, Yesilipek A, Locatelli F, Peters C. Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study. Blood Adv. 2024 Jan 23;8(2):416-428. doi: 10.1182/bloodadvances.2023010591. PMID: 37738088.